Wikipedia -WSS

Wikipedia

author：hotspot 2025-09-28 20:32:49 - browse：94

The headquarter of Biotechnology company Ionis Pharmaceuticals, consists of glass windows, pale yellow exteriors and plants outside the building — biotech coverage from STAT — courtesy Ionis Pharmaceuticals

Ionis Pharmaceuticals, a California company that pioneered a whole class of RNA-targeted medicines, reported on Friday that a pair of late-stage trials showed that its experimental therapy for hereditary angioedema benefitted patients — including those taking drugs currently on the market.

In one of the Phase 3 trials, dubbed OASIS, patients with hereditary angioedema, a rare disease characterized by severe bouts of swelling, were given injections of donidalorsen either monthly or every two months. Those in the former group had an 81% lower monthly rate of swelling attacks after 25 weeks than patients given a placebo, while the reduction compared to placebo was 55% for those treated every two months.

The other study, OASISplus, found that donidalorsen’s benefits deepened and converged after up to an additional year of treatment, with swelling attack rates dropping by 92% to 93% regardless of how often patients were dosed. Notably, this study also tracked patients who switched over to donidalorsen from existing therapies meant to prevent swelling attacks, including drugs sold by Takeda and BioCryst Pharmaceuticals. Patients who switched to the Ionis drug saw their swelling attack rates drop by 62% compared to previous treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Woodcock on FDA’s accelerated approval and her next chapter

entertainment

WSS

Novavax promises a turnaround & Lilly roils the obesity market

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Sports medicine is finally prioritizing gender equality

ChatGPT in medicine: STAT answers readers' burning questions

23andMe had bad news about my health. I wish a person had delivered it

Apple is now the first public company to be valued at $3 trillion

entertainment

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

How one medical school became remarkably diverse

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

In Memoriam: Notable people who died in 2023

Juul spent big to court Black leaders to promote its e

DIEP, the 'gold standard' of breast reconstruction, is under threat

Congressmen charge Covid hearing ‘could have been an email’

What does generative AI mean for health care? We asked experts

Cybersecurity threat forces Lurie Children's to take systems offline

How one medical school became remarkably diverse

Peter Hotez and the public health issue of online harassment

entertainment

Malaria cases in Florida and Texas: Here’s what you need to know

FDA drug safety: Singulair case shows systemic surveillance flaws

Cancer drug shortages should be causing more outrage

FDA drug safety: Singulair case shows systemic surveillance flaws

The real point of Kenneth Smith’s execution by nitrogen gas

Hepatitis C has a cure — but many Americans still lack access to it

entertainment

focus

focus

Wikipedia